A Johnson & Johnson promotion for rheumatoid arthritis drug Remicade is misleading because it makes unsupported claims about the drug’s effectiveness and omits important information about risks, U.S. regulators said in a letter released on Monday.

The Food and Drug Administration told the company to immediately stop using materials that contain the misleading information.

An eight-page sales material presented to doctors “suggests Remicade is safer and more effective than has been demonstrated by substantial evidence or clinical experience,” the FDA said in a letter dated Feb. 11 and posted on the agency’s Web site on Monday.

Michael Parks, a spokesman for Johnson & Johnson unit Centocor that makes Remicade, said the company was reviewing the letter and “will work with the FDA to resolve any issues.”

Johnson & Johnson shares fell 65 cents, or about 1 percent, in afternoon trading on the New York Stock Exchange.